Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Rosa Gómez EspínIsabel Nicolás De PradoMayte Gil-CandelMarta González CarriónLorena Rentero RedondoCarles Iniesta-NavalónPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)
this real-life study shows the association between ustekinumab trough concentration and clinical and biochemical remission and we suggest an optimal cut-off point higher than 2.2 µg/ml. Further studies are needed to confirm the findings and to identify the optimal cut-off in different disease outcomes and disease phenotypes.